Zelira TherapeuticsASX:ZLD Days Payable is 114,229.79 as of Jun. 2025, which is 6870% above its 10-year median of 1,638.97. The stock has 7 warning signs investors should review. Among 706 Biotechnology companies, Zelira Therapeutics ranks better than 99.29% on this metric.
The historical rank and industry rank for Zelira Therapeutics's Days Payable or its related term are showing as below:
ASX:ZLD'
s Days Payable Range Over the Past 10 Years
Min: 484.92 Med: 1638.97 Max: 147595.19
Current: 147595.19
During the past 13 years, Zelira Therapeutics's highest Days Payable was 147595.19. The lowest was 484.92. And the median was 1638.97.
ASX:ZLD's Days Payable is ranked better than 99.29% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs ASX:ZLD: 147595.19
Zelira Therapeutics's Days Payable
increased
from Jun. 2024 (17,011.96) to Jun. 2025 (114,229.79).
It may suggest that Zelira Therapeuticsdelayed paying its suppliers.
Zelira Therapeutics Days Payable Related Terms
Zelira Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Zelira Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ZLD vs ENSC, PPCB, ACUT: Days Payable Comparison
For the Biotechnology subindustry, Zelira Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zelira Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zelira Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Zelira Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zelira Therapeutics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zelira Therapeutics (ASX:ZLD) has a Days Payable of 114,229.79 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zelira Therapeutics and its competitors. This is 6870% above median its historical median of 1,638.97. Over the past decade, Zelira Therapeutics' Days Payable has ranged from 484.92 to 147,595.19. According to the industry distribution chart, Zelira Therapeutics ranks #5 out of 706 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Zelira Therapeutics' Days Payable too high?
Zelira Therapeutics' current Days Payable of 114,229.79 is 6870% above median its 10-year median of 1,638.97. Over the past 10 years, this metric has ranged from a low of 484.92 to a high of 147,595.19. The Biotechnology industry median Days Payable is 113.56. Zelira Therapeutics' value of 114,229.79 is 100489.8% above this industry median. Based on the distribution chart, Zelira Therapeutics ranks #5 out of 706 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Zelira Therapeutics' Days Payable compare to ENSC and PPCB?
According to the Biotechnology industry distribution chart, Zelira Therapeutics ranks #5 out of 706 companies for Days Payable. This places Zelira Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Zelira Therapeutics' value of 114,229.79 is 100489.8% above this benchmark. Historically, Zelira Therapeutics' own Days Payable has ranged from 484.92 to 147,595.19 over the past decade. While the company's 10-year median is 1,638.97 vs. the industry median of 113.56, Zelira Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zelira Therapeutics's current Days Payable of 114,229.79 is 100489.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zelira Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zelira Therapeutics's current Days Payable is 114,229.79, which is 6870% above median its own 10-year median of 1,638.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Days Payable of 114,229.79. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Days Payable is 114,229.79, which is 6870% above median its 10-year median of 1,638.97 and 100489.8% above the Biotechnology industry median of 113.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Days Payable is 114,229.79 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ZLD has been successfully added to your 